BNTX vs VALN
BioNTech SE and Valneva SE, side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | BNTX | VALN |
|---|---|---|
| Revenue | €2.9B | €174.7M |
| Net income | €-1.1B | €-115.2M |
| Gross margin | 77.6% | 38.7% |
| Net margin | −39.6% | −66.0% |
| Return on equity | 3.1% | — |
| Diluted EPS | −€4.70 | −€0.68 |
| Dividend / share | — | — |
| Payout ratio | −0.0% | — |
| Free cash flow | €280.9M | €-57.3M |
| Equity | €493.5M | — |
| Net debt / equity | — | — |
| Current ratio | 7.54× | 2.38× |
| Revenue CAGR 5y | 42.9% | 9.6% |
| Profit CAGR 5y | — | — |
BNTX bills 16.4× the revenue of VALN, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | BNTX | VALN |
|---|---|---|
| FY2025 | €2.9B | €174.7M |
| FY2024 | €2.8B | €169.6M |
| FY2023 | €3.8B | €153.7M |
| FY2022 | €17.3B | €361.3M |
| FY2021 | €19.0B | €348.1M |
| FY2020 | €482.3M | €110.3M |
| FY2019 | €108.6M | €126.2M |
Net income by year
Bottom line
| Fiscal year | BNTX | VALN |
|---|---|---|
| FY2025 | €-1.1B | €-115.2M |
| FY2024 | €-665.3M | €-12.2M |
| FY2023 | €930.3M | €-101.4M |
| FY2022 | €9.4B | €-143.3M |
| FY2021 | €10.3B | €-73.4M |
| FY2020 | €15.2M | €-64.4M |
| FY2019 | €-179.1M | €-811,000 |
Advertisement
AdSense · Rectangle 336×280
More in this industry